Trijardy XR Shortage: What Providers and Prescribers Need to Know in 2026

An increasing number of patients prescribed Trijardy XR are reporting difficulty filling their prescriptions at retail pharmacies. While Trijardy XR is not currently listed on the FDA Drug Shortage database as an active shortage, localized supply disruptions — driven by high demand for empagliflozin-containing products, single-source manufacturing, and early-2026 formulary transitions — are creating real access barriers for patients. This guide provides clinical context, substitution options, and workflow strategies to help prescribers manage their patient panels effectively.

Current Availability Status (2026)

Trijardy XR (empagliflozin 10/25 mg / linagliptin 5 mg / metformin HCl ER 1000 mg) is manufactured exclusively by Boehringer Ingelheim. As of early 2026, it is not on FDA shortage status, but distribution patterns suggest uneven availability across regional pharmacy networks. Contributing factors include:

• Expanded empagliflozin indications (HFrEF, CKD) increasing aggregate demand for the drug class
• No FDA-approved generic for the fixed-dose combination, limiting substitutability
• January 2026 formulary updates creating short-term prescription surges at the pharmacy distribution level
• Variable stocking patterns at smaller pharmacies due to the high acquisition cost of the brand

Clinical Considerations for Therapeutic Substitution

Trijardy XR is a fixed-dose combination of three distinct drug classes. When substituting, clinicians must account for all three components — particularly when the patient's indication includes cardiovascular risk reduction:

Empagliflozin Component (SGLT2 Inhibitor)

Empagliflozin has a Class I recommendation from the ADA for patients with T2DM and established ASCVD or high CV risk. For patients with this indication, substituting with another SGLT2 inhibitor is clinically reasonable:

• Dapagliflozin (Farxiga): 5 or 10 mg daily. FDA-approved for T2DM, HFrEF, and CKD. Generally considered equivalent for glycemic and CV indications. Often better stocked than empagliflozin products.
• Canagliflozin (Invokana): 100 or 300 mg daily. FDA-approved for T2DM and diabetic nephropathy. Note the boxed warning for increased lower limb amputation risk — factor this into your risk-benefit assessment.

Linagliptin Component (DPP-4 Inhibitor)

Linagliptin (Tradjenta, 5 mg once daily) can be prescribed separately as a standalone tablet. Alternatively, sitagliptin (Januvia, 100 mg once daily) is a common DPP-4 substitution — note that sitagliptin requires dose adjustment for patients with renal impairment (eGFR 30-45: 50 mg/day; eGFR < 30: 25 mg/day), whereas linagliptin does not require dose adjustment in renal impairment. Generic sitagliptin is also available, improving affordability.

Metformin Component (Biguanide)

Generic metformin hydrochloride extended-release is widely available at all major pharmacies and costs under $15/month. The transition from Trijardy XR to separate metformin ER should be straightforward — maintain the same total daily dose and confirm the patient is aware they will receive a separate pill for this component.

Available Combination Products as Substitutes

For patients who benefit from pill burden reduction, consider these fixed-dose alternatives:

• Glyxambi (empagliflozin/linagliptin): Preserves both Trijardy XR's SGLT2 and DPP-4 components. Prescribe with separate generic metformin ER for full equivalence.
• Synjardy XR (empagliflozin/metformin ER): Preserves SGLT2 and metformin. Add standalone Tradjenta 5 mg for full equivalence.
• Janumet XR or generic sitagliptin/metformin ER: Lower cost; lacks SGLT2 component. Appropriate if CV indication is not the primary driver.

Prior Authorization Considerations When Switching

Switching to a different SGLT2 inhibitor (e.g., dapagliflozin) or a different drug class may trigger a new prior authorization requirement. Plan for 24-72 hours for commercial payers; Medicare Advantage plans may take 3-5 business days for standard review. For urgent situations, request a peer-to-peer review or expedited PA. Providing relevant clinical documentation (A1C, CVD history, renal function) upfront can speed approval.

Workflow Recommendations for Your Practice

To reduce the administrative burden of availability-related calls and prescription changes:

• Use medfinder for providers to check real-time pharmacy availability before routing prescriptions — reducing callback volume from patients who can't fill
• Pre-authorize a therapeutic alternative (e.g., Farxiga) on file for patients taking Trijardy XR with a cardiovascular indication, so the substitution PA is already in place if needed
• Advise patients to fill their 30-day supply a few days before running out to provide buffer time for sourcing
• Keep manufacturer samples on hand for 1-2 week bridge supply during acute availability gaps
• Recommend independent pharmacies or mail-order to patients experiencing repeated out-of-stock situations

Patient Communication Points

When patients call about Trijardy XR availability, staff can direct them to check pharmacy stock using medfinder before escalating to a provider callback. Patients can also be referred to the Trijardy XR shortage patient guide for self-service next steps, including how to find it at nearby pharmacies and what to ask their care team.